CR20120177A - NEW COMPOUNDS OF SPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME FOR THE TREATMENT OF DIABETES - Google Patents

NEW COMPOUNDS OF SPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME FOR THE TREATMENT OF DIABETES

Info

Publication number
CR20120177A
CR20120177A CR20120177A CR20120177A CR20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A CR 20120177 A CR20120177 A CR 20120177A
Authority
CR
Costa Rica
Prior art keywords
diabetes
spiropiperidine
treatment
same
new compounds
Prior art date
Application number
CR20120177A
Other languages
Spanish (es)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20120177A publication Critical patent/CR20120177A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula:o una sal del mismo farmacéuticamente aceptable así como también una composición farmacéutica, y un método para tratar diabetes.A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.

CR20120177A 2009-10-15 2012-04-12 NEW COMPOUNDS OF SPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME FOR THE TREATMENT OF DIABETES CR20120177A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
CR20120177A true CR20120177A (en) 2012-06-06

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120177A CR20120177A (en) 2009-10-15 2012-04-12 NEW COMPOUNDS OF SPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME FOR THE TREATMENT OF DIABETES

Country Status (24)

Country Link
US (1) US8383642B2 (en)
EP (1) EP2488500A1 (en)
JP (1) JP2013508279A (en)
KR (1) KR20120051777A (en)
CN (1) CN102574807A (en)
AR (1) AR078522A1 (en)
AU (1) AU2010307094A1 (en)
BR (1) BR112012008889A2 (en)
CA (1) CA2777775A1 (en)
CL (1) CL2012000921A1 (en)
CO (1) CO6531458A2 (en)
CR (1) CR20120177A (en)
DO (1) DOP2012000105A (en)
EA (1) EA201270560A1 (en)
EC (1) ECSP12011799A (en)
IL (1) IL218344A0 (en)
MA (1) MA33662B1 (en)
MX (1) MX2012004420A (en)
NZ (1) NZ598972A (en)
PE (1) PE20121437A1 (en)
TN (1) TN2012000152A1 (en)
TW (1) TW201124415A (en)
WO (1) WO2011046851A1 (en)
ZA (1) ZA201202560B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010109329A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
MX2011009824A (en) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as trpa1 modulators.
AR078948A1 (en) * 2009-11-30 2011-12-14 Lilly Co Eli SPYROPIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES
CA2785674A1 (en) 2009-12-25 2011-06-30 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
ES2891092T3 (en) 2011-03-11 2022-01-26 Intercontinental Great Brands Llc Multi-layer confectionery product forming method
JP5420796B2 (en) 2011-04-27 2014-02-19 持田製薬株式会社 Novel 3-hydroxyisothiazole 1-oxide derivative
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
TWI537262B (en) 2011-08-17 2016-06-11 美國禮來大藥廠 A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
BR112015010779A2 (en) 2012-11-16 2017-07-11 Bristol Myers Squibb Co dihydropyrazole gpr40 modulators
KR101569522B1 (en) * 2013-04-18 2015-11-17 현대약품 주식회사 Novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, preparation method thereof, and pharmaceutical composition for use in preventing or treating metabolic diseases containing the same as an active ingredient
KR20160077213A (en) 2013-11-14 2016-07-01 카딜라 핼쓰캐어 리미티드 Novel heterocyclic compounds
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
DK3207928T3 (en) 2014-10-17 2021-04-26 Hyundai Pharm Co Ltd Composite composition containing novel 3- (4- (benzyloxy) phenyl) hex-4-inonic acid derivative and another active ingredient, for the prevention or treatment of metabolic diseases
CN109666027A (en) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 GPR40 agonist compound of a kind of amide structure and application thereof
PT3737470T (en) 2018-01-08 2023-03-02 Celon Pharma Sa 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7105359B2 (en) 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド PD-1/PD-L1 inhibitor
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
UY39222A (en) 2020-05-19 2021-11-30 Kallyope Inc AMPK ACTIVATORS
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229736D1 (en) 2001-04-18 2008-12-18 Euro Celtique Sa SPIROINDEN AND SPIROINDAN COMPOUNDS
CN101108825A (en) * 2003-04-04 2008-01-23 麦克公司 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
WO2005046682A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4859665B2 (en) 2004-03-30 2012-01-25 武田薬品工業株式会社 Alkoxyphenylpropanoic acid derivatives
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
SI2202216T1 (en) * 2007-10-26 2012-10-30 Japan Tobacco Inc Spiro-ring compound and use thereof for medical purposes
US8158792B2 (en) 2007-11-21 2012-04-17 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (en) 2009-11-30 2011-12-14 Lilly Co Eli SPYROPIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES

Also Published As

Publication number Publication date
CL2012000921A1 (en) 2012-09-14
DOP2012000105A (en) 2013-01-31
KR20120051777A (en) 2012-05-22
AU2010307094A1 (en) 2012-04-19
ECSP12011799A (en) 2012-07-31
MA33662B1 (en) 2012-10-01
IL218344A0 (en) 2012-04-30
MX2012004420A (en) 2012-05-08
JP2013508279A (en) 2013-03-07
EP2488500A1 (en) 2012-08-22
US20110092531A1 (en) 2011-04-21
AR078522A1 (en) 2011-11-16
WO2011046851A1 (en) 2011-04-21
TN2012000152A1 (en) 2013-12-12
PE20121437A1 (en) 2012-10-26
CA2777775A1 (en) 2011-04-21
BR112012008889A2 (en) 2019-09-24
TW201124415A (en) 2011-07-16
CO6531458A2 (en) 2012-09-28
NZ598972A (en) 2013-06-28
EA201270560A1 (en) 2012-09-28
US8383642B2 (en) 2013-02-26
ZA201202560B (en) 2013-09-25
CN102574807A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
CR20120177A (en) NEW COMPOUNDS OF SPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME FOR THE TREATMENT OF DIABETES
ECSP12011930A (en) NEW SPYROPIPERIDINE COMPOUNDS
BR112012026767A2 (en) compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, method for treating or preventing disorders, and use of a compound or salt
ECSP099436A (en) ACILAMINOPIRAZOLES AS FGFR INHIBITORS
CO6620055A2 (en) Certain amino-pyrimidines, compositions thereof and methods for the use thereof
UY32062A (en) BETA-SECRETASA INHIBITORS
UY32153A (en) PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS
UY31215A1 (en) PIRIMIDINE MORPHOLINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY.
NI200900184A (en) USE OF PI3K-ALPHA QUINAXOLINE INHIBITING COMPOUNDS FOR THE TREATMENT OF CANCER.
CL2013002417A1 (en) Compounds derived from fluoropyridinone; pharmaceutical composition comprising them; and its use in the treatment of bacterial infections.
DOP2011000260A (en) FUSIONATED PYRIMIDINS
CL2014001154A1 (en) Antibiotic derivative compounds of 2-oxo-oxazolidin-3,5-diyl of formula i; pharmaceutical composition; use for the prevention or treatment of a bacterial infection.
DOP2014000018A (en) NEW DERIVATIVE OF 1,2,3,4-TETRAHYDROQUINOLINE USEFUL FOR THE TREATMENT OF DIABETES
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
CR11684A (en) REPLACED DIHYDROPIRAZOLONES OF HIF-PROPIL-4- AS HYDROXYLASE INHIBITORS
AR085616A1 (en) INHALABLE PHARMACEUTICAL COMPOSITION UNDERSTANDING GLICOPIRROLATE, USE
CL2014002845A1 (en) Compounds derived from pyrazole sglt1 inhibitors; method to treat diabetes; pharmaceutical composition; use of the compound for the treatment of type 1 and type 2 diabetes.
ECSP10010168A (en) BENZOTIAZOLAS AS MODULATORS OF THE GHRELINA RECEPTOR
ECSP13012653A (en) OXAZOL COMPOUNDS [5,4-b] PIRIDIN-5-ILO AND ITS USE FOR CANCER TREATMENT
CO6460763A2 (en) ECTOPARASITICID METHODS AND FORMULATIONS
AR080025A1 (en) DERIVATIVES OF 8-AZA-BICYCLE [3,2,1] OCT-3-ILOXI) -CROMEN-2-ONA, USEFUL AS INHIBITORS OF THE RECOVERY OF THE MONOAMINE NEUROTRANSMITTER
CO6382120A2 (en) CYCLOPROPYL COMPOUNDS
UY33806A (en) NOVEDOUS IMIDAZOQUINOLINE COMPOUNDS, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATED BY TLR7?
BRPI1015983A2 (en) compound, use of the compound, method for treating a patient, and pharmaceutical composition.
CL2007003806A1 (en) Compounds derived from n- (2h-pyrazol-3-yl) -amide, fgfr inhibitors; pharmaceutical composition comprising said compounds; its preparation process; and its use for the treatment of cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)